Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0
|
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Huang, D. [3 ]
Sun, Y. [4 ]
Wu, L. [5 ]
Zhou, C. [6 ]
Zhou, J. [7 ]
Guo, Y. [8 ]
Chen, L. [9 ]
Shao, J. [9 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China
[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Selpercatinib; RET fusion-positive NSCLC; China; ORR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.01
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [41] Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients
    Sireci, A.
    Morosini, D.
    Rothenberg, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S401 - S401
  • [42] Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study
    Griesinger, Frank
    Curigliano, Giuseppe
    Subbiah, Vivek
    Baik, Christina S.
    Tan, Daniel S. W.
    Lee, Dae H.
    Misch, Daniel
    Garralda, Elena
    Kim, Dong-Wan
    van der Wekken, Anthonie J.
    Gainor, Justin F.
    Paz-Ares, Luis
    Liu, Stephen, V
    Kalemkerian, Gregory P.
    Bowles, Daniel W.
    Mansfield, Aaron S.
    Lin, Jessica J.
    Smoljanovic, Vlatka
    Rahman, Ahmadur
    Zalutskaya, Alena
    Louie-Gao, Melinda
    Boral, Andy L.
    Mazieres, Julien
    FUTURE ONCOLOGY, 2024, 20 (06) : 297 - 306
  • [43] Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China
    Lu, S.
    Shen, L.
    Wang, Q.
    Chen, H.
    Zhao, Y.
    Li, Y.
    Segall, G.
    Dyachkova, Y.
    Khanal, M.
    Zhang, X.
    Ding, D.
    Shao, J.
    Wang, Q.
    Gao, Y.
    Pang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S550 - S551
  • [44] Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Gautschi, O.
    Drilon, A.
    Tan, D. S. W.
    Oxnard, G. R.
    McCoach, C.
    Goto, K.
    Park, K.
    Alonso Casal, G.
    de Braud, F.
    French, P.
    Soldatenkova, V.
    Besse, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S835 - S835
  • [45] RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET ONCOLOGY, 2016, 17 (12): : 1623 - +
  • [46] Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study
    Liao, Dehua
    Long, Minghui
    Zhang, Jiwen
    Wei, Xingyu
    Li, Fei
    Yan, Ting
    Yang, Desong
    LUNG CANCER, 2024, 196
  • [47] Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Chen, M. F.
    Rosen, E.
    Falcon, C.
    Repetto, M.
    Yang, S. R.
    Chang, J.
    Kris, M. G.
    Rekhtman, N.
    Donoghue, M.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [48] Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
    Sousa, D.
    Afonso, M.
    Rocha, D.
    Craveiro, A.
    Martins, S.
    Barata, J.
    Valente, M. L. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S413 - S414
  • [49] Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
    Loong, H.
    Goto, K.
    Park, K.
    Ohe, Y.
    Nishio, M.
    Cho, B. C.
    Kim, Y. J.
    French, P.
    Soldatenkova, V.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S231 - S232
  • [50] Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
    Wang, Lei
    You, Yafei
    He, Wenzhuo
    Hou, Yu
    Li, Lan
    Wang, Li
    Jiang, Chang
    Yi, Jiahong
    Xia, Yaoxiong
    Xia, Liangping
    FRONTIERS IN MEDICINE, 2025, 12
12345